top of page
Applied StemCell, Inc.

iPSC/MSC Cell Manufacturing <GMP Facility Opening 5/12/2023>

ASC Announces the Expansion of its cGMP Manufacturing Facility to Support Cell and Gene Therapy Open House 5/12 | ASC

 
 

Applied StemCell, Inc. (ASC), a leading cell and gene therapy CRO/CDMO focused on supporting the research community and biotechnology industry for their needs in developing and manufacturing cell and gene products, today announced the expansion of its Current Good Manufacturing (cGMP) facility. ASC has successfully carried out cell banking and product manufacturing projects in its current cGMP suite and is now set on building 4 additional cGMP cleanrooms, cryo-storage space, and a process development and QC/QA space. The expansion of the facility will increase its cell banking and cell product manufacturing capacity and allow ASC’s team of experts to work simultaneously on multiple manufacturing projects such as iPSC generation, gene editing, differentiation, and cell bank manufacturing for safe and efficacious therapeutic products.

Applied StemCell would like to invite you to our Open House on Friday, May 12th at 1 PM. The event will include a small reception and a guided tour of our new cleanrooms designated for GMP MSC/iPSC cell manufacturing, plasmid manufacturing, and cell banking. If you would like to join us, please contact us at info@appliedstemcell.com.
 
We hope to see you soon!
 

About Applied StemCell, Inc.

ASC has a Drug Manufacturing License from the California Department of Public Health, Food and Drug Branch (FDB). It has a Quality Management System (ISO 13485 certified) and established cGMP-compliant protocols for cell banking and manufacturing, iPSC generation, genome editing, iPSC differentiation, and cell product manufacturing. With over 13 years of gene-editing and stem cell expertise, ASC offers comprehensive and customized cell and gene CRO/CDMO solutions. Its core iPSC and genome editing (CRISPR and TARGATTTM) technologies, facilitate site-specific, large cargo (up to 20kb) transgene integration and the development of allogenic cell products.

Media Contact:
Maki Ogawa
Marketing Director, Applied StemCell, Inc.
408-773-8007
maki.ogawa@appliedstemcell.com

4087738007

Makiko Ogawa

Service Provider:

USA Europe Japan China Other areas CDMO CRO Consulting service Biologics Gene therapy Cell therapy Discovery Preclinical Clinical

Demand Type:

Looking for biotech/pharma

Expiration:

May 12, 2023

Back to Business

bottom of page